Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5-to 11-Year Olds

Eric A. F. Simoes, Nicola P. Klein,Charu Sabharwal, Alejandra Gurtman,Nicholas Kitchin, Benita Ukkonen, Piotr Korbal,Jing Zou, Xuping Xie,Uzma N. Sarwar, Xia Xu,Stephen Lockhart, Luke Cunliffe, Claire Lu,Hua Ma, Kena A. Swanson,Kenneth Koury, Pei-Yong Shi,David Cooper, Ozlem Tureci,Kathrin U. Jansen, Ugur Sahin,William C. Gruber

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY（2023）

引用 0|浏览3

暂无评分

摘要

In this ongoing study, substantially increased ancestral SARS-CoV-2 neutralizing responses were observed 1 month after a third 10-mu g BNT162b2 dose given to 5 to 11-year olds versus neutralizing responses post-dose 2. After dose 3, increased neutralizing responses against Omicron BA.1 and BA.4/BA.5 strains were also observed. The safety/tolerability profile was acceptable. (NCT04816643)

查看译文

关键词

COVID-19,BNT162b2 vaccine,children,booster,immunogenicity,safety

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要